ArticleScientific reports2025
In vitro assessment of the osteogenic and antibacterial capabilities of Mg-MOF particles with encapsulated Levofloxacin within polydopamine.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent advances in metal-organic frameworks for the diagnosis and treatment of breast cancer.Discover nano · 2026Review
- Multitechnological integration advances musculoskeletal regeneration: synergistic progress of organoids, 3D/4D bioprinting, single-cell omics and artificial intelligence.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Infectious bone defect is a condition where infection and bone defect occur simultaneously. The simultaneous achievement of effective antimicrobial management and enhanced bone regeneration continues to present a major hurdle in musculoskeletal therapeutics. To address these limitations, we have developed a novel osteoconductive material, this material (PDA@Mg-MOF-LEV) consists of Magnesium-based metal-organic frameworks (Mg-MOF) particles loaded with the antibiotic levofloxacin (LEV) and coated with polydopamine (PDA), which integrates photothermal therapy with antibiotic delivery to combat bacterial drug resistance and facilitate bone tissue regeneration. Under near-infrared (NIR) irradiation, PDA@Mg-MOF-LEV particles demonstrate superior antibacterial efficacy and enhanced osteogenic potential. Drug release studies indicate that NIR irradiation significantly increases LEV release by 337% and Mg ions release by 196% compared to standard conditions. Furthermore, in vitro antibacterial assays confirm that NIR irradiation markedly enhances the antibacterial activity of PDA@Mg-MOF-LEV particles, achieving inhibition rates of 97.5 ± 1.45% against Escherichia coli (E. coli) and 98.5 ± 2.27% against Staphylococcus aureus (S. aureus). The photothermal therapy mediated by NIR irradiation not only enhances antibacterial efficacy but also directly stimulates osteogenic differentiation and calcium deposition in mBMSCs, positioning PDA@Mg-MOF-LEV as a multi-modal therapeutic platform for infective osteogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.